Rockwell Medical (RMTI) Gains from Sales and Divestitures (2018 - 2019)

Rockwell Medical (RMTI) reported Gains from Sales and Divestitures of $96542.0 for Q3 2019, down 1.99% quarter-over-quarter from $98500.0 in Q2 2019.

Rockwell Medical (RMTI) Gains from Sales and Divestitures (2018 - 2019) Analysis & Trends

Rockwell Medical has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $96542.0 in Q3 2019.

For the quarter ending Q3 2019, Gains from Sales and Divestitures changed N/A year-over-year to $96542.0; the trailing twelve-month figure through Sep 2019 stood at $96542.0 (changed N/A YoY), and the FY2018 full-year result was $98500.0, changed N/A from the prior year.
Gains from Sales and Divestitures for Q3 2019 stood at $96542.0, down from $98500.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $98500.0 in Q4 2018, with the low at $96542.0 in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	38.77 Bn	35.04 Bn	1.97 Bn
2	Zoetis	34.11 Bn	32.16 Bn	1.62 Bn
3	United Therapeutics	23.68 Bn	21.53 Bn	648.10 Mn
4	Aurora Cannabis	16.48 Bn	16.40 Bn	33.43 Mn
5	Neurocrine Biosciences	16.19 Bn	14.88 Bn	800.70 Mn
6	Elanco Animal Health	11.44 Bn	11.01 Bn	785.00 Mn
7	Alkermes	7.28 Bn	6.77 Bn	-116.06 Mn
8	Lantheus Holdings	6.48 Bn	5.98 Bn	230.92 Mn
9	Hims & Hers Health	6.35 Bn	5.60 Bn	396.79 Mn
10	Rockwell Medical	26.31 Mn	2.42 Mn	2.90 Mn

Download Data